Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Accolade 12.3

13 Jun 2019 07:00

RNS Number : 0247C
Sopheon PLC
13 June 2019
 

SOPHEON PLC

("Sopheon" or the "Company")

 

New Sopheon Release Enhances Corporate Adaptability

 

Accolade® 12.3 enables local flexibility to react quickly to markets, eases risk management, and frees up teams for high-value contributions.

 

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, today releases the latest version of its Accolade® Enterprise Innovation Management solution, extending the corporate adaptability strategy introduced in Accolade 12.2.

 

While digital and business transformation are top corporate priorities, it is widely recognized that most corporations are unable to respond quickly to external conditions or move fast enough to be the market disruptor and not the disrupted. They lack an operating model that simultaneously offers both connectivity and flexibility. Operational business units, segments and regional entities need the freedom to respond to their markets while remaining aligned with the corporate strategy and key performance indicators. Along with this, employees need to be freed from menial administrative tasks to focus on higher-value contributions that move the dial. Sopheon calls this capability "corporate adaptability."

 

 "Corporations will not survive in the digital age unless they adopt a new digital operating model that allows them to move faster than their outside markets while operating within corporate strategic guidelines and governance," said Andy Michuda, Sopheon CEO. "Accolade 12.3 has been created in partnership with a number of clients who are some of the most progressive, world-leading companies, in an effort to enable traditional market leaders to compete and win in today's fast-paced economy."

 

Accolade 12.3 introduces new capabilities aimed at solving for this challenge including features that offer:

 

· More localized flexibility without compromise to corporate governance

· Transparency of dependencies and notifications for risk management

· Enhanced user experience and time savings through smart automation

 

Tristen Branson, Product Innovation Manager at Australian Paper, added: "We are very pleased with Accolade 12.3 advances in user friendliness that will save our users time in their work, while providing management the information they need for better decision making."

 

For further information contact:

Barry Mence (Chairman)Arif Karimjee (CFO)

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes/Giles Rolls (Corporate Finance)Alice Lane (ECM)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 250 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRALLFLRRRIFLIA
Date   Source Headline
27th Jan 20117:00 amPRNTrading Statement
9th Dec 20107:00 amPRNAmendment to the Terms of Convertible Loan Stock
16th Nov 20107:00 amPRNContract Win
4th Nov 20107:00 amPRNInterim Management Statement
27th Aug 201010:30 amPRNGrant of Options
26th Aug 20107:00 amPRNHalf-yearly Report
22nd Jul 20107:00 amRNSTrading Update
15th Jun 20105:31 pmPRNResult of AGM
15th Jun 20107:00 amPRNAGM Statement
18th May 20107:00 amRNSAfton Chemical Selects Idea Lab
6th May 20107:00 amPRNInterim Management Statement
25th Mar 20107:00 amPRNFinal Results
22nd Mar 20107:00 amRNSiSUSTAINT Alliance Launched
3rd Feb 20107:00 amRNSSopheon Team wins TARDEC Contract
28th Jan 20107:00 amPRNTrading Update
24th Dec 20097:01 amRNSExtension of GEM Equity Line
2nd Dec 20097:00 amRNSVision Strategist Version 5.0 Launched
3rd Nov 20097:00 amPRNInterim Management Statement
2nd Oct 20093:43 pmPRNISSUE OF CONVERTIBLE LOAN STOCK
27th Aug 20097:00 amPRNHalf-yearly Report
16th Jun 200912:34 pmPRNResult of AGM
16th Jun 20097:00 amPRNAGM Statement
19th May 20097:00 amPRNProduct Launch
7th May 20097:00 amPRNInterim Management Statement
26th Mar 20097:00 amPRNFinal Results
18th Mar 20097:00 amRNSBostik Implements Sopheon's Accolade System
11th Mar 20097:00 amRNSContract Win
11th Feb 20097:00 amRNSEnhanced Version of Accolade? Launched
28th Jan 20097:00 amPRNTrading Update
21st Jan 20097:00 amRNSSopheon Partners with Maxsoft
4th Nov 20087:00 amPRNInterim Management Statement
28th Aug 20087:00 amPRNHalf-yearly Report
27th Jun 20083:47 pmPRNDirector/PDMR Shareholding
25th Jun 20087:00 amPRNGrowth Milestone
10th Jun 20087:00 amPRNAGM Statement
16th May 20087:00 amPRNDirector/PDMR Shareholding
15th May 20087:00 amPRNInterim Management Statement
6th May 200810:00 amPRNNotice of AGM
29th Apr 20087:02 amRNSContract Win
1st Apr 200810:00 amPRNGrant of Options
27th Mar 20087:00 amPRNFinal Results
6th Feb 20087:01 amRNSProduct Development
25th Jan 20087:00 amPRNTrading Update
21st Dec 200710:30 amPRNTrading Update
25th Oct 20077:00 amPRNTrading Update
16th Oct 20072:38 pmBUSBeiersdorf Implements Sopheon System in Support of Product Innovation Strategy
16th Oct 20077:01 amRNSContract Win
10th Oct 20072:45 pmBUSLeading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System
10th Oct 20077:01 amRNSContract Win
1st Oct 20077:02 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.